Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-12-07
2000-05-23
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514278, 514299, 514311, 514327, 514329, 514330, 514345, 514348, 514354, 514355, 514456, 544251, 546102, 546207, 546220, 546222, 546218, 546223, 546224, 546229, 546242, 546243, 546244, 546248, 546246, 546247, 549401, 549402, 549403, A01N 4354, A01N 4316, C07D21140, C07D31104, C07D47100
Patent
active
060666420
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD OF THE INVENTION
The present invention relates to adenosine receptor antagonists, pharmaceutical compositions, and methods of selectively blocking adenosine receptors in a mammal. The present invention also relates to methods of treating various medical disorders with adenosine receptor antagonists.
BACKGROUND OF THE INVENTION
The use of caffeine and other alkylxanthines as physiological stimulants is well known. The principle mechanism by which caffeine and other alkylxanthines act as physiological stimulants is by blocking the effects of the ubiquitous neuromodulator adenosine. Daly, "Mechanism of action of caffeine", in Caffeine, Coffee and Health, (S. Garattini, ed), Chapter 4, pp. 97-150 (1993). Adenosine is produced locally in response to increased activity or stress to the system. This feedback mechanism allows the organ to compensate for the stress by decreasing energy demand (depressant activity) and increasing oxygen supply (e.g., by vasodilation). Bruns, Nucleosides & Nucleotides, 10, 931-944 (1991).
Adenosine plays several key physiological roles. In addition to its role in intermediary metabolism, adenosine displays a number of receptor-mediated physiological actions, including dilation of coronary vessels, inhibition of platelet aggregation, and inhibition of lipolysis. Bruns et al., Proc. Nat. Acad. Sci. U.S.A., 77, 5547-5551 (1980). Adenosine receptors, belonging to the superfamily of the G protein-coupled receptors, are generally divided into two major subclasses, A.sub.1 and A.sub.2, on the basis of the differential affinities of a number of adenosine receptor agonists and antagonists for the receptors, their primary structures, and the secondary messenger systems to which they couple. Thus, A.sub.2 receptors, which can be further subdivided into A.sub.2a and A.sub.2b, stimulate adenylate cyclase, whereas A.sub.1 receptors may couple to a variety of secondary messenger systems, including those involved in the inhibition of adenylate cyclase, the inhibition or stimulation of phosphoinositol turnover, the activation of guanylate cyclase, the activation of potassium influx, and the inhibition of calcium influx (van Galen et al., Med. Res. Rev., 12, 423-471 (1992); Jacobson et al., J. Med. Chem., 35, 407-422 (1992)).
Recently, a novel adenosine receptor was identified on the basis of its primary structure and cloned from rat brain (Zhou et al., Proc. Natl. Acad. Sci. U.S.A., 89, 7432-7436 (1992)) and rat testes (Meyerhof et al., FEBS Lett., 284, 155-160 (1991)). The putative transmembrane domains of the novel adenosine receptor, which has been designated the A.sub.3 receptor, show 58% identity with the canine A.sub.1 receptor and 57% with the canine A.sub.2a receptor. Like the A.sub.1 receptor, the A.sub.3 receptor is negatively coupled to adenylate cyclase (Zhou et al.).
The distribution of the A.sub.3 receptor is found primarily in the central nervous system (CNS) (Zhou et al.), brain, testes (Meyerhof et al.), and immune system, where it appears to be involved in the modulation of release from mast cells of mediators of the immediate hypersensitivity reaction (Ramkumar et al., J. Biol. Chem., 268, 16887-16890 (1993)). It is believed that A.sub.3 -selective compounds will have utility in the therapeutic and/or prophylactic treatment of cardiac disease, infertility, kidney disease, and CNS disorders.
It is further believed that selective A.sub.3 -adenosine receptor antagonists should serve as cerebroprotective, anti-asthmatic, or anti-inflammatory agents. Beaven et al., Trends Pharmacol. Sci., 15, 13-4 (1994); Jacobson et al., Drugs of the Future, 20, 689-699 (1995); von Lubitz et al., Eur. J. Pharmacol., 275, 23-29 (1995).
Copending U.S. patent applications Ser. No. 08/274,628, filed Jul. 13, 1994, and Ser. No. 08/396,111, filed Feb. 28, 1995, disclose certain A.sub.3 selective agonists, particularly N.sup.6 -benzyladenosine-5'-uronamide and related substituted compounds, xanthine riboside derivatives, pharmaceutical compositions comprising such compounds, and the method
REFERENCES:
patent: 3932645 (1976-01-01), Meyer et al.
patent: 4048171 (1977-09-01), Bossert et al.
patent: 4380547 (1983-04-01), Materne
patent: 4532248 (1985-07-01), Franckowiak et al.
patent: 5502064 (1996-03-01), Junge et al.
Ali et al., "A.sub.3 Adenosine Receptor in the Airways of Allergic Rabbits," Experimental Biology, (1997).
Ares et al., "The Binding of Flavonoids to Adenosine Receptors." Abstracts of Papers of the American Chemical Society, 209, 190-MEDI, (1995).
Carruthers et al., "Adenosine A.sub.3 Receptors: Two in One Won't Go," Trends in Pharmacological Sciences, 14 8, 290-291 (1993).
Eynde et al., "Old Reagents, New Results: Aromitization of Hantzsch 1,4-Dihydropyridines with Manganese Dioxide and 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone," Tetrahedron, 51 23, 6511-6516 (1995).
Francis et al., "Structure-Activity Profile of a Series of Novel Triazoloquinazoline Adenosine Antagonists," J. Med. Chem., 31, 1014-1020 (1988).
Hu et al., "Interaction of Dihydropyridine Calcium Channel Agonists and Antagonists with Adenosine Receptors," Pharmacology and Technology, 61, 121-125 (1987).
Ismail et al., "Effect of Calcium Channel Antagonists in Modifying the Inhibitory Influence of Adenosine on Insulin Secretion." Arzneimittel-Forschung/Drug Research, 45 8, 865-868 (1995).
Jacobson et al., "A.sub.3 -Adenosine Receptors: Design of Selective Ligands and Therapeutic Prospects," Drugs of the Future, 20 7, 686-699 (1995).
Jacobson et al., "A.sub.3 Adenosine Receptors: Novel Ligands and Paradoxical Effects," Trends Pharmcol. Sci., 19, 184-191 (1998).
Jacobson et al., "Pharmacological Characterization of Novel A.sub.3 Adenosine Receptor-Selective Antagonists," Neuropharmacology, 36, 1157-1165 (1997).
Jiang et al., "6-Phenyl-1,4-dihydropyridine Derivatives as Potent and Selective A.sub.3 Adenosine Receptor Antagonist," J. Med. Chem., 39, 4667-4675 (1996).
Jiang et al., "Structure Activity Relationships of 4-Phenylethynyl-6-Phenyl-l, 4-Dihydropyridines as Highly Selective A.sub.3 Adenosine Receptor Antagonists," J. Med. Chem., 40, 2596-2608 (1997).
Marangos, "Calcium Antagonists and the Brain Adenosine System," Chemical Abstracts, 105: 127265g (1986).
Meade, et al., "In Vivo Role of the Adenosine A.sub.3 Receptor: N.sup.6 2-(4-Aminophenyl)ethyladenosine Induces Bronchospasm in BDE Rats by a Neurally Mediated Mechanism involving Cells resembling Mast Cells," Journal of Pharmacology and Experimental Therapeutics, 279 5, 1148-1156, 1990.
Mustafa et al., "Adenosine-Induced Bronchoconstriction and Contraction of Airway Smooth Muscle from Allergic Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Adenosine A.sub.1 Receptor.sup.1," Journal of Pharmacology and Experimental Therapeutics, 268 3, 1328-1334 (1994).
Murphy et al., "Adenosine Receptor Binding and Specific Receptors for Calcium Channel Drugs," Chemical Abstracts, 99: 187500x (1983).
Pfister, "Rapid, High-Yield Oxidation of Hantzsch-Type 1,4-Dihydropyridines with Ceric Ammonium Nitrate," Synthesis, 8, 689-690 (1990).
Van Rhee et al., "Interaction of 1,4-Dihydropyridine and Pyridine Derivatives with Adenosine Receptors: Selectivity for A.sub.3 Receptors," Journal of Medicinal Chemistry, 39 15, 2980-2989 (1996).
Van Rhee et al., "Tetrahydrobenzothiophenone Derivatives as a Novel Class of Adenosine Receptor Antagonists," Journal of Medicinal Chemistry, 39 2, 398-406 (1996).
Yao, Y. et al., "Adenosine A.sub.3 Receptor Agonists Proteet HL-60 and U-937 Cells from Apoptosis Induced by A.sub.3 Antagonists," Biochem. Biophys. Res. Comm., 232, 317-322 (1997).
Jacobson Kenneth A.
Jiang Ji-Long
Karton Yishai
Kim Yong-Chul
Van Rhee Albert M.
Covington Raymond
Kight John
The United States of America as represented by the Department of
LandOfFree
Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquina does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquina, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquina will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1837293